Clinical significance of the dose modification of enfortumab vedotin monotherapy for advanced urothelial carcinoma., PMID:40163660
Oncology: What You May Have Missed in 2024., PMID:40163865
Impact of Initial Relative Dose Intensity on Tumor Response and Survival Outcomes in Enfortumab Vedotin Monotherapy for Previously Treated Advanced Urothelial Carcinoma: A Real-world Analysis From a Multicenter Study., PMID:40175211
Lines of Therapy for Locally Advanced/Metastatic Urothelial Carcinoma: The New Paradigm., PMID:40184571
Editorial Comment to "Impact of Skin Adverse Events on Prognosis in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Real-World Multicenter Study"., PMID:40195588
Organ-specific tumor response to enfortumab vedotin in metastatic urothelial carcinoma: a multicenter retrospective study., PMID:40197493
Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas., PMID:40198857
[Enfortumab-vedotin in combination with pembrolizumab as first-line treatment for advanced/metastatic urothelial carcinoma]., PMID:40204543
Nectin-4 expression patterns and therapeutics in oncology., PMID:40209851
High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy., PMID:40215164
Cost-Effectiveness of Enfortumab Vedotin and Pembrolizumab for First-Line Metastatic Urothelial Cancer in the United States., PMID:40220863
Strategies to overcome resistance to enfortumab vedotin and pembrolizumab for patients with urothelial carcinoma: harnessing present knowledge for future advances., PMID:40225697
Balancing effectiveness, toxicity, and individualization: enfortumab vedotin in advanced urothelial cancer., PMID:40226067
Clinical Response to Enfortumab Vedotin and Pembrolizumab in a Patient with Vaginal Squamous Cell Carcinoma: A Case Report., PMID:40235861
Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer: comparison between patients from a Dutch nationwide cohort and KEYNOTE-045., PMID:40250101
Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin., PMID:40252634
Evaluation of Nectin-4 and Trop-2: Implications for Patient Outcomes and Therapy in Penile Cancer., PMID:40252843
Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study., PMID:40277744
Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab Vedotin., PMID:40295006
Steroid Premedication Impact on Efficacy and Cutaneous Toxicity of Enfortumab Vedotin for Advanced Urothelial Carcinoma., PMID:40295014
Treatment Outcomes After Progression With Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma., PMID:40295063
Advancements in systemic therapy for muscle-invasive bladder cancer: A systematic review from the beginning to the latest updates., PMID:40296876
Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis., PMID:40300922
Salvage Surgery Following Remarkable Tumor Shrinkage With Enfortumab Vedotin in Advanced Urothelial Carcinoma., PMID:40336728
Complete Response after Avelumab Maintenance Therapy: Successful Management of Metastatic Urothelial Carcinoma., PMID:40352709
Increased Risk of Hyperglycemia in Advanced Urothelial Cancer Patients Treated with Enfortumab Vedotin: A Systematic Review and Meta-Analysis., PMID:40358559
Immune Checkpoint Inhibitors and Antibody-Drug Conjugates in Urothelial Carcinoma: Current Landscape and Future Directions., PMID:40361519
Evaluation of Optimal Sequential Treatment Patterns and Clinical Outcomes in Patients With Advanced Urothelial Carcinoma Treated With First-Line Platinum-Based Chemotherapy: A Multicenter Collaborative Study., PMID:40375459
The patients have spoken: how does enfortumab vedotin impact quality of life?, PMID:40376537
Progress of antibody-drug conjugates in the treatment of locally advanced or metastatic urothelial carcinoma: opportunities and challenges., PMID:40377724
Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder cancer., PMID:40401457
A Case of Generalized Anhidrosis That Developed During Treatment With Enfortumab Vedotin., PMID:40401791
Erythema multiforme-like eruption with severe epidermal necrosis after administration of enfortumab vedotin., PMID:40417899
E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors-design and rationale., PMID:40421891
Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and Research Symposium., PMID:40422537
Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and/or Immune Checkpoint Inhibitor Therapy: A Multicenter Analysis., PMID:40425390
Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions., PMID:40433388
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study., PMID:40449498
Adverse cardiac events associated with antibody drug conjugates in cancer patients: a retrospective analysis on the FAERS database and randomized controlled trials., PMID:40455883
Enfortumab Vedotin Plus Pembrolizumab in Untreated Locally Advanced or Metastatic Urothelial Carcinoma: 2.5-Year Median Follow-Up of the Phase III EV-302/KEYNOTE-A39 Trial., PMID:40460988
Nectin-4-Targeting Radiotracers: Novel Theranostic Agents for Precision Oncology in Cancer., PMID:40474033
Two Cases of Enfortumab Vedotin-Induced Drug Eruption Diagnosed Based on the Distinctive Epidermal Mitotic Figures in Patients Receiving Combination Therapy With Pembrolizumab., PMID:40476598
Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma., PMID:40479863
Enfortumab Vedotin-Induced Diabetic Ketoacidosis and Acute Tubulointerstitial Nephritis Requiring Intensive Care in the Treatment of Advanced Urothelial Carcinoma: A Case Report., PMID:40487556
Enfortumab vedotin induced interstitial lung disease: A first case report with pathological evidence from transbronchial lung cryobiopsy., PMID:40496844
Mechanistic Insights into Anti-Nectin4-VcMMAE-Induced Ocular Toxicity: From Cellular Uptake Pathways to Molecular Modification., PMID:40507807
Avelumab maintenance in advanced urothelial carcinoma: real-world data from Northern Spain (AVEBLADDER study)., PMID:40514610
Optimizing enfortumab vedotin plus pembrolizumab therapy., PMID:40526099
Enfortumab vedotin-induced widespread vesiculobullous eruption mimicking disseminated herpetic infection in a patient with metastatic urothelial carcinoma., PMID:40526955
Enfortumab vedotin therapy complicated by bullous dermatitis: A case report., PMID:40530174
The Evolution of Antibody-Drug Conjugates: A Positive Inflexion Point, PMID: 32223669
Updates in the management and future landscape of urothelial carcinoma, PMID: 33143526
Antibody-drug conjugates for the treatment of urothelial carcinoma, PMID: 32589063
Emerging biomarkers in urothelial carcinoma: Challenges and opportunities, PMID: 32920502
Antibody-Drug Conjugates in Bladder Cancer, PMID: 30112436
Cutaneous reactions with enfortumab vedotin: A case series and review of the literature, PMID: 34235241
Benefit of nectin-4 targeting with enfortumab vedotin confirmed, PMID: 33692500
Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy-A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin, PMID: 34206980
Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction, PMID: 33747934
New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?, PMID: 34148797
Enfortumab Vedotin: Nursing Perspectives on the Management of Adverse Events in Patients With Locally Advanced or Metastatic Urothelial Carcinoma, PMID: 33739346
Severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin, PMID: 32860247
Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma, PMID: 33895011
Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?, PMID: 33019653
Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin, PMID: 33604101
Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma, PMID: 32751328
Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date, PMID: 33603337
Benefit with enfortumab vedotin confirmed, PMID: 33649567
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial, PMID: 33991512
Enfortumab Vedotin in Advanced Urothelial Carcinoma. Reply, PMID: 34192441
Enfortumab Vedotin in Advanced Urothelial Carcinoma, PMID: 34192440
Enfortumab vedotin for cisplatin-ineligible urothelial cancer, PMID: 33991513
Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma, PMID: 30865407
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma, PMID: 33577729
Enfortumab vedotin is safe and effective, PMID: 34031573
Antibody-Drug Conjugates in Urothelial Carcinomas, PMID: 32008109
A rare presentation of enfortumab vedotin-induced toxic epidermal necrolysis, PMID: 33319007
Targeting Nectin-4 in Bladder Cancer, PMID: 28634245
The emerging role of antibody-drug conjugates in urothelial carcinoma, PMID: 32552213
Antibodies to watch in 2019, PMID: 30516432
Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin, PMID: 32982431
Enfortumab Vedotin, PMID: 33630480
Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma, PMID: 33301805
Management of metastatic bladder cancer, PMID: 31030123
The biology and rationale of targeting nectin-4 in urothelial carcinoma, PMID: 33239713
Flexural Exanthema From Enfortumab Vedotin, PMID: 32542157
Enfortumab vedotin - next game-changer in urothelial cancer, PMID: 33325754
Enfortumab Vedotin Checks Urothelial Cancer, PMID: 31519705
Enfortumab vedotin shows promise in solid tumours, PMID: 32066546
Antibodies to watch in 2020, PMID: 31847708
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma, PMID: 32962979
A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma, PMID: 31444589
Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma, PMID: 31526130
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma, PMID: 32031899
Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma, PMID: 32945172
Enfortumab Vedotin in urothelial cancer, PMID: 33447264
Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma, PMID: 31823332
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models, PMID: 27013195
Enfortumab vedotin to treat urothelial carcinoma, PMID: 32406880
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy, PMID: 31356140
For research use only. Not for human or drug use.
